Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTBG BR9601: Epirubicin followed by CMF vs CMF in Early Breast Cancer
NCT00003012Phase 3Completed
- Sponsor
- Scottish Cancer Therapy Network
- Start
- Oct 1996
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of epirubicin in breast cancer, sponsored by Scottish Cancer Therapy Network. Started Oct 1996; status: completed.
02
Drugs
epirubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00003012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003012.